Abstract
I-sA ␤ 1-40 was inhibited by anti-RAGE (receptor for advanced glycation end products) antibody (63%) and by acetylated low density lipoproteins (33%). Consistent with these data, transfected cultured cells overexpressing RAGE or macrophage scavenger receptor (SR), type A, displayed binding and internalization of 125

Introduction
Amyloid ␤ (A ␤ ), 1 a heterogenous, 39-43 amino acid peptide, is the main constituent of the senile plaques and cerebrovascular deposits, the primary lesions in Alzheimer's disease (AD) (1, 2) . A ␤ is considered to be central to the pathology of AD because it may be neurotoxic-directly by inducing oxidant stress and indirectly by activating microglia (3) (4) (5) . It has been suggested that the presence of pathological "chaperone" proteins in brain and/or other predisposing factors is critical for the cytotoxic effects of A ␤ (1). A soluble monomeric form of A ␤ (sA ␤ ) is normally produced by different types of cells (6) and is present in the circulation and cerebrospinal fluid (CSF) (7, 8) and in brain parenchyma (9) . The 40-amino-acid peptide A ␤ accounts for approximately 90% of A ␤ released from cells in culture (6) and is the predominant form of cerebrovascular amyloid (10, 11) . The longer 42-residue peptide, A ␤ 1-42 , accounts for only 10% of secreted A ␤ but is the major constituent of senile plaques (12) . Recent quantitative analysis has demonstrated that 31% of all plaques contain A ␤ 1-40 , while 60% are labeled with A ␤ 1-42 (13) .
The origin of the A ␤ deposited in cerebral vasculature and brain is uncertain. According to the "neuronal theory" A ␤ is produced locally in brain. In contrast, the "vascular theory" proposes that A ␤ originates from the circulation, and that circulating sA ␤ could contribute to neurotoxicity if it crosses the brain capillary endothelium, which comprises the blood-brain barrier (BBB) in vivo (14) . Transport of several peptides and proteins through the brain capillary endothelium is possible via receptor-mediated transcytosis (15) (16) (17) (18) (19) . It has been suggested that specific receptor mediates BBB transport of circulating sA ␤ 1-40 in rodents and nonhuman primates (14, (20) (21) (22) . However, direct transport of sA ␤ 1-40 across the BBB in humans has not been studied, and it is not known whether specific binding and/or transport mechanisms for sA ␤ 1-40 exist at human brain microvascular endothelial cells (HBMECs). In addition, previously used in vivo techniques (14, (21) (22) (23) lack the resolution to compare peptide binding and transport at the apical versus basolateral side of brain endothelium. We hypothesized that specific receptor(s) for sA ␤ 1-40 are present in human brain capillaries, and that their endothelial cellular distribution may favor asymmetrical binding and transport of peptide at the BBB. Thus, apical-to-basolateral transport may allow circulating peptide to enter the brain and vessel wall which could be associated with its cytotoxic effects. In contrast, basolateral-to-apical transport may favor clearance of sA ␤ from brain into blood that may ultimately decrease its tissue levels. An in vitro model of human BBB (24, 25) was used to test the above hypothesis and to characterize apical versus basolateral HBMEC binding, endocytosis, and transcytosis of a synthetic peptide homologous to human sA ␤ . The roles of recently described receptors for free A ␤ , including the receptor for advanced glycation end products (RAGE) (4) and scavenger receptor (SR) (5), were studied.
Methods
Chemicals. Peptide DAEFRHDSGYEVHHQKLVFFAEDVGSNK-GAIIGLMVGGVV (sA ␤ 1-40 ), homologous to residues 672-711 of ␤ -precursor amyloid protein was custom synthesized at the W.M. Keck Facility at Yale University using solid-phase N -tert -butyloxycarbonyl chemistry. Peptide was purified by reverse-phase high pressure liquid chromatography (HPLC) using a C18 column (Vydac, Hesperia, CA) and a linear gradient of 0-80% acetonitrile in 0.05% trifluoroacetic acid (TFA). The final product was lyophilized and characterized by analytical reverse phase HPLC, amino acid analysis, and laser desorption spectrometry. The secondary structure of sA ␤ 1-40 was determined by circular dichroism and consisted of 0% ␣ -helix, 27.7% ␤ -sheet, 0.6% ␤ -turn; and 71.7% random coil. The reverse synthetic peptide VVGGVMLGIIAGKNSGVDEAFFVLKQHHVEY-GSDHRFEAD (A ␤ 40-1 ) was purchased from Sigma Chemical Co. (St. Louis, MO). sA ␤ 1-40 was labeled with Na[ 125 I] (13.7 mCi/ g; Amersham Corp., Arlington Heights, IL) using Iodobeds (Pierce Chemical Co., Rockford, IL) following the manufacturer's instructions. To revert the potential sA ␤ 1-40 oxidation at Met35 due to the radioiodination procedure, the peptide was subjected to reduction with 0.1 M dithiothreitol for 6 h before purification. Labeled peptides were separated from free iodine and oxidation derivatives by reverse-phase HPLC using a 5-m C4 narrow bore column (Vydac) and a 45-min linear gradient from 0-70% acetonitrile. Protein elution was monitored by absorbance at 280 nm and radioactivity evaluated in a gamma counter (Beckman Instruments, Fullerton, CA). The resulting specific activity of [ 125 I]sA ␤ 1-40 was 7.6 Ci/ g, and Ͼ 97% TCA precipitable. Changes in the secondary structure due to the radioiodination procedure were evaluated by circular dichroism. Spectra in the far ultraviolet range (260-190 nm) were recorded at 241C with a spectropolarimeter (model J-720; Jasco Inc., Easton, MD) using a cell path of 0.1 cm at a peptide concentration of 0.15 mg/ml in 20 mM Tris, pH 7.4.
Isolation of human brain capillaries. Human brain capillaries were isolated from small fragments of cerebral cortex obtained from surgical resections from three adults with seizure disorder, as we recently described (24) . Portions with no pathologic lesions were used. Briefly, brain specimens devoid of large blood vessels were homogenized in DMEM containing 2% fetal bovine serum (FBS) using a Dounce homogenizer (VWR, San Diego, CA). The homogenate was centrifuged in 15% dextran in DMEM for 10 min at 10,000 g. The pellets containing crude microvessels were further digested in a solution containing 1 mg/ml collagenase/dispase in DMEM-S for 1 h at 37 Њ C. Microvascular capillaries were isolated by absorption to a column of glass beads and washing off the beads. Cell viability was Ͼ 95% as judged by a trypan blue exclusion test.
Cultures and characterization of HBMECs. The human brain microvessels were plated on rat-tail collagen-coated dishes or glass coverslips and cultured in RPMI 1640-based medium with growth factors (24) , FBS, NuSerum, endothelial cell growth supplement, heparin (5 U/ml), L -glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids, vitamins, penicillin, and streptomycin (100 U/ml) (24) . Cultures were incubated at 37 Њ C in a humid atmosphere of 5% CO 2 . The resulting HBMECs were positive for factor VIIIrelated antigen, carbonic anhydrase IV, Ulex Europeus Agglutinin I, and took up acetylated low density lipoprotein (AcLDL, ligand for endothelial SR [5] ) demonstrating their endothelial origin. HBMECs also expressed ␥ -glutamyl transpeptidase, indicating their brain origin. Detailed procedures regarding characterization of HBMECs were as we previously reported (24) .
In a separate set of experiments, cytospin slides of HBMECs were prepared with a cytospin centrifuge (Shandon Lipshaw Corp., Pittsburgh, PA), and slides were rehydrated and stained with polyclonal rabbit antihuman anti-RAGE antibodies (4) . Secondary peroxidase-labeled antibodies and development with diaminobenzidine were used. Sections were lightly stained with hematoxylin. Fluorescent-labeled DiI-AcLDL was used to demonstrate the presence of SR (5) . HBMECs were incubated with DiI-AcLDL (10 g/ml) for 4 h at 37 Њ C, fixed with 2.5% glutaraldehyde in phosphate-buffered saline (PBS), and viewed. Pictures were taken with a fluorescence microscope (Nikon, Tokyo, Japan) as described (24) .
In vitro model of the BBB. Using the HBMECs, the BBB in vitro model was constructed in inserts with collagen-fibronectin-coated polycarbonate in Transwell membrane filters (Costar Corp., Cambridge, MA) as we reported (25) . A single monolayer of HBMECs was produced by placing 200 l of cell suspension containing 5 ϫ 10 5 cells in the upper chamber of a 24-well tissue culture insert and 1,000 l in the lower chamber. Analysis of the BBB by transmission electron microscopy (TEM) in 5-day-old primary cultures revealed flat monolayers of endothelial cells covering the porous membrane completely. The apical surface of endothelial cells had neither microvilli nor cytoplasmic processes. The cytoplasm of HBMECs contained elongated nuclei, free ribosomes, few mitochondria, and endoplasmic reticulum. Typical rod-shaped Weibel Palade bodies were observed with a dark striated appearance. Bundles of intermediate filaments were located under the basolateral cytoplasmic membrane, and microtubules were evenly distributed in the HBMEC cytoplasm. Occasionally two or three HBMECs were overlaid on one another. Formation of gap and tight junctions were found between the thin cytoplasmic processes of HBMECs. As we reported, the presence of astrocytes did not positively affect the tightness of the HBMEC monolayer in this model (26) , and therefore they were not used in the present studies.
sA [28] [29] [30] [31] . Although the exact molecular mechanism for the inhibitory effect of PAO on endocytosis is not known, it has been suggested that this trivalent arsenical forms a stable ring with vicinal sulfhydryl groups, affects phosphoinositide metabolism, and at higher concentrations reduces cellular energy stores, but at a concentration used to inhibit endocytosis its other cellular actions are minimized (28, 29) . PAO inhibits internalization of several peptide ligands (e.g., epidermal growth factor, insulin) (29) , and at the BBB receptor-mediated endocytosis of insulin (30) as well as endothelial endocytosis of dynorphins (31) . by HBMECs were also studied in several assay buffer and HBMEC samples with HPLC to corroborate the results of TCA precipitation analysis. Prior to extraction and HPLC fractionation, the HBMECs were exposed to acid wash solution (0.2 M acetic acid and 0.5 M NaCl for 6 min) to remove surface-bound sA␤ . HBMEC samples were then prepared by hypotonic lysis as reported (32) . Briefly, HBMECs were homogenized in water containing protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, and 1 mM p-amino-benzamidine) and centrifuged at 100,000 g for 1 h at 4ЊC. The supernatant was then lyophilized. The resulting material was dissolved in 0.1% TFA in water, pH 2.1, before injection onto the HPLC column. The aliquots of assay buffer samples from upper and lower chamber were diluted in 0.1% TFA in water, pH 2.1, before injection onto the HPLC column. Separation was achieved using a C4 column (Vydac, The Separation Group) with a 30-min linear gradient of 25-83% acetonitrile in 0.1% TFA at a flow rate of 1 ml/min. Under these conditions, the sA␤ standard eluted at 15.5 min. Column eluants were monitored at 214 nm. The eluted fractions were collected and counted using a gamma counter (Beckman Instruments). Protein content of the BMEC monolayers was determined by the Lowry method (33) .
All measurements were done in triplicate.
[ to BMECs were estimated by nonlinear least squares regression using the software program SAAM II (University of Washington, Seattle, WA), with initial parameter estimates determined by Scatchard analysis (34) .
sA␤ transendothelial transport across HBMEC monolayers. These experiments were carried out at 37ЊC. Samples (0.2 ml) were removed from both the apical (upper) and basolateral (lower) chambers to determine the extent of tracer passage across the BMEC monolayer. To control for nonspecific 1/2 to correct for the nonspecific leakage and the differences in inulin and sA␤ diffusion across the coated membrane. When basolateral-to-apical transport of sA␤ was studied, the same formula was applied, but in this case the dose represented the radioactivity of intact sA␤ added to the basolateral chamber, and the sample represented the radioactivity of sA␤ in the upper chamber. Since transendothelial basolateral-to-apical transport of sA␤ corrected for nonspecific leakage was undetectable, the transport parameters described below were determined only for apical-tobasolateral transport. Degradation of sA␤ following transport across the HBMECs was studied in several assay buffer samples from the apical and basolateral chambers with HPLC (31) using the procedure as described above. The HPLC analysis was performed to corroborate the results of TCA precipitation analysis. The permeability-surface area (PS) product for sA␤ in the apical-to-basolateral direction was calculated using the equation PS ϭ X/(A ϫ t ϫ C D ) where X and C D are concentrations of 125 I-sA␤ in lower and upper chamber, respectively, t is the time of exposure, and A is the surface area, as reported (16) . The inhibition of 125 I-sA␤ 1-40 transport in apical-tobasolateral direction was studied in the presence of unlabeled sA␤ (0.5-150 nM), 150 nM sA␤ 40-1 and different concentrations of anti-RAGE antibody (5-40 g/ml) and AcLDL (50-800 g/ml). The transendothelial apical-to-basolateral influx, J in , of 125 I-sA␤ in the presence of various concentrations of unlabeled peptide in the upper chamber, C, was calculated as (16, 19) : J in ϭ PS ϫ C ϫ q, where q is the amount of protein (in mg) per number of cells in HBMEC monolayers occupying the surface area A available for transendothelial transport. Kinetic transport Michaelis-Menten parameters, K m (Michaelis affinity constant) and V max (maximal transport capacity) for intact sA␤ were calculated with a nonlinear regression analysis using SAAM II program as reported (19) .
Radioligand binding and internalization studies in transfected cultured cells overexpressing RAGE or macrophage SR type A. For the RAGE overexpression system, Chinese hamster ovary (CHO) cells were transiently transfected with pcDNA3/RAGE (human RAGE) using lipofectamine (GIBCO/BRL, Grand Island, NY). RAGE expression in these cells was characterized by immunoblotting and immunocytochemistry as described (35) . For the SR overexpression system, Bowes cells stably transfected to overexpress the macrophage SR type A, characterized as previously described (36), were employed. In brief, cultures were grown to confluence ‫ف(‬ 10 6 cells/well), medium was aspirated, cells were washed with Hank's balanced salt solution over 10 min (5 min/wash) at room temperature, and then binding buffer (minimal essential medium containing fatty acid-free bovine serum albumin 0.1%) was added (50 l/well). For radioligand binding studies, cultures were briefly (20 min) pretreated with paraformaldehyde (2%) after the washing procedure to prevent internalization of bound ligand as described previously (37) . Wells were incubated with 125 I-sA␤ 1-40 alone or in the presence of an 100-fold molar excess of unlabeled sA␤ for 120 min at 37ЊC. This incubation time was required for apparent maximal binding at the lowest tracer concentrations. After the incubation period, wells were rapidly washed four times in ice-cold binding buffer over 30 s (this time period was sufficiently rapid to prevent significant dissociation of bound ligand [Ͻ 5-10%]). Cell-bound radioactivity was eluted by incubating wells for 5 min at 37ЊC with PBS containing heparin (10 mg/ml) or with saline containing NP-40 (1%) for 5 min at 37ЊC. Specific binding, the difference between total binding (that observed with 125 I-sA␤ 1-40 alone) and nonspecific binding (that observed with 125 I-sA␤ in the presence of an 100-fold excess of unlabeled sA␤ ) was analyzed by the method of Klotz and Hunston (37), using nonlinear least squares analysis (Enzfitter). Specific binding according to these methods was identical following elution with heparin or NP-40.
For internalization studies, similar methodology was employed, except cells were not exposed to paraformaldehyde. The experiment was also performed at 37ЊC for 1 min. Following washing to remove unbound tracer, cultures were sequentially exposed to heparin-containing buffer (as above), to elute surface-bound radioactivity, and then NP-40, to elute cell-associated radioactivity not accessible to heparin (i.e., internalized ligand). For morphologic studies, cultures were incubated with nonradioactive sA␤ according to the same protocol described above for tracking internalized ligand. Then, cultures were fixed in paraformaldehyde (2%) with/without NP-40 (0.1%) and studied for localization of A␤ by immunocytochemistry using anti-A␤ 1-40 immunoglobulin G (IgG) as the primary antibody (QCB, Hopkinton, MA) and affinity purified fluorescein isothiocyanate-labeled goat anti-rabbit IgG as the secondary antibody (Sigma Chemical Co.).
Results
The analysis of HBMECs by TEM in 5-day-old primary cultures revealed a flat and continuous monolayer of cells bound by the tight junctions (Fig. 1 A) . At 37ЊC, the specific binding of sA␤ was found only at the apical side and was absent from the basolateral side (Fig. 1 B) . The total binding of 125 IsA␤ 1-40 (0.5 nM) to the apical cell surface was rapid and progressively increased within the first 5 min. A steady-state level was reached between 5 and 60 min. The majority of binding (75-80%) was resistant to removal by acid wash, indicating incorporation into apical membrane or endocytosis at physiological temperature. The temperature dependence of sA␤ binding and internalization was evident (Fig. 1 C) . At 4ЊC, the total binding at the apical side was significantly reduced, associated with a decrease in acid-resistant binding (i.e., intracellular binding). There was a minimal degree of metabolism or degradation of 125 I-sA␤ by HBMECs at 37ЊC (Fig. 1 D) to the apical side was saturable in the presence of increasing concentrations of unlabeled sA␤ (Fig. 1 E, inset) . Specificity of sA␤ binding was reflected by the minimal influence of 150 nM reverse sA␤ 40-1 peptide. Scatchard analysis of the binding data at 4ЊC indicated the presence of two independent sA␤ binding sites (Fig. 1 E, main graph) . The nonlinear regression analysis indicated a high-affinity binding site with a dissociation constant K Fig. 1 F, the amount of sA␤ that was internalized by HBMECs (i.e., resistant to re- moval by acid wash) was significantly reduced by 20 M PAO, an endocytic inhibitor. In all experiments, the HBMEC uptake of simultaneously exposed 14 C-inulin was barely above the background level, indicating the absence of a nonspecific leak into the cells and minimal entrapping of the tracer in the medium between the cells at the sites of junctional complexes.
Transendothelial transport of sA␤ was asymmetrical in the apical-to-basolateral direction. At 37ЊC, transport from the upper to the lower chamber was significantly higher for intact 125 I-sA␤ 1-40 (TCA-precipitable) than for 14 C-inulin, an extracellular space marker transported across the monolayer by a nonspecific diffusion (leakage) through the intercellular pores or junctions (Fig. 2 A) . In contrast, basolateral-to-apical transport of sA␤ was comparable to inulin. Apical-to-basolateral transport of sA␤ across the endothelial monolayer corrected for the nonspecific leakage (inulin transport) was time dependent and sensitive to reduced temperature (Fig. 2 B) . When corrected for the nonspecific leakage, basolateral-to-apical transport of (Fig.  2 D) . Figure 3 A indicates that anti-RAGE antibody (20 g/ml) inhibits by about 63% the binding of 125 I-sA␤ to the apical side of the BBB. AcLDL at a maximal inhibitory concentration of 800 g/ml was able to produce about 32% inhibition of binding by anti-RAGE ϩ AcLDL was 95.6%. As shown by the inset, there was a progressive dose-dependent inhibition of 125 I-sA␤ 1-40 binding by anti-RAGE at 4ЊC in the presence of a maximal inhibitory concentration of AcLDL; the maximal inhibition with anti-RAGE was achieved at 20 g/ml. Figure 3 B shows that at 37ЊC, anti-RAGE (20 g/ml) inhibits apicalto-basolateral transport of 125 I-sA␤ by about 36%, and further increase in the anti-RAGE concentration did not produce greater inhibition (Fig. 3 B, inset) . The addition of AcLDL at maximal concentrations did not affect transcytosis of 125 I-sA␤ . The expression of RAGE and SR in the present HBMEC system was shown by immunocytochemistry (RAGE) and uptake of endothelial SR ligand, fluorescent DiI-AcLDL (Fig. 3, C  and D) . We previously reported that glycoprotein 330, gp330/ megalin, is expressed at the BBB, but does not participate in binding and transport of free A␤ (38) . This has been confirmed in the present BMEC model and the expression of gp330/megalin shown by immunocytochemistry with mouse monoclonal 1H12 anti-human anti-gp330 antibodies, kindly provided by R. McCluskey, Harvard University (data not shown; Stins et al., unpublished observations). Figure 3 E illustrates that unlabeled LDL (low density lipoproteins) at concentrations as high as 800 g/ml does not affect the uptake of 125 I-AcLDL (1 nM) exposed for 1 h to the apical side of the HBMEC monolayers, indicating that LDL receptor does not participate in uptake of AcLDL, as shown previously (39, 40) .
Our results with cultured HBMECs led us to analyze directly the potential involvement of RAGE and SR in cellular handling of sA␤ 1-40 using transfected cell systems in which the (Fig. 4 A, BI-II) . Transiently transfected CHO cells demonstrated specific binding of 125 I-sA␤ 1-40 compared with mock-transfected controls (Fig. 4 C) . Cells were briefly exposed to paraformaldehyde (2%) to prevent internalization during binding assays performed at 37ЊC, and RAGE-dependent 125 I-sA␤ 1-40 binding was dose-dependent with K d Ӎ 72.0Ϯ42.1 nM. Cell-associated radioactivity was restricted to the surface, as shown by complete elution of specifically bound 125 I-sA␤ with heparin under these conditions (Fig. 4 D, fixed cell) . If heparin solution was followed by dissolution of the cells in NP-40 containing buffer, no additional specifically bound tracer was recovered using paraformaldehydetreated cells. In contrast, when experiments were performed at 37ЊC without paraformaldehyde, endocytosis of cell-associated 125 I-sA␤ 1-40 resulted in two pools of ligand (Fig. 4 D, unfixed   cell) ; most ligand was still on the cell surface ‫ف(‬ 82-83% by 3 h). However, a component of specifically bound ligand was present in a heparin-resistant, NP-40-elutable pool ‫ف(‬ 17-18%). Immunocytochemistry was performed using an antibody specific for A␤ . To visualize internalized ligand, following the incubation period at 37ЊC, cell surface sA␤ 1-40 was eluted with heparin-containing buffer. The absence of surfaceassociated ligand following heparin treatment of RAGE-transfected CHO cells was confirmed by immunocytochemistry of nonpermeabilized cells (Fig. 4 E, I ). Next, after heparin elution, cultures were permeabilized with NP-40, and the presence of a pool of sA␤ 1-40 present in a granular pattern was observed (Fig. 4 E, II) . Thus, the latter sA␤ represented internalized ligand.
Similar radioligand and internalization studies were performed using stably transfected Bowes cells overexpressing SR type A. This scavenger receptor was selected for our studies in view of its identification in brain microvasculature (39) . Surface binding was evaluated at 37ЊC using cells briefly exposed (Fig. 5 A) . Pretreatment of cultures with paraformaldehyde prevented internalization of cell-bound 125 I-sA␤ , as complete elution of specifically bound ligand was observed with heparin ( Fig. 5 B, fixed cell) . Under these conditions, no increments in specifically bound 125 IsA␤ was observed following NP-40 elution. In contrast, experiments with live (i.e., unfixed) cells and 125 I-sA␤ performed at 37ЊC demonstrated the appearance of a sizeable pool of heparin-resistant cell-associated tracer. Following heparin elution of cell surface-bound tracer, NP-40 elution recovered an additional ‫ف‬ 70% of total specifically cell-associated radioactivity. Immunocytochemistry was used to confirm the presence of internalized A␤. Following incubation of cultures with sA␤ at 37ЊC, cultures were exposed to heparin to elute surface-bound ligand (Fig. 5 C, I ). Subsequent permeabilization of these cells with NP-40 resulted in the appearance of a pool of sA␤ in a granular pattern (Fig. 5 C, II) which represented internalized ligand.
Discussion
These studies indicate that sA␤ is bound and internalized at the apical side of the HBMECs cultured on membrane inserts I-sA␤ (54 nM) alone or in the presence of 100-fold excess unlabeled sA␤ for 2 h at 37ЊC. Cultures were then washed, and exposed to heparincontaining elution buffer (heparin) followed by NP-40-containing elution buffer (NP-40). Specifically bound ligand under each condition is shown as a percentage of total specific binding. (EI-EII) Visualization of cell-associated sA␤ . RAGEtransfected CHO cells were incubated with sA␤ 1-40 at 37ЊC. Cells were exposed to heparin containing buffer to elute surface bound A␤ (EI), or were exposed to heparin followed by permeabilization with NP-40 containing buffer (EII). Immunocytochemistry to visualize A␤ was performed as described in the text.
by two specific acceptor sites. The binding constant of the high-affinity sA␤ 1-40 BBB sites (K d ϭ 7.8 nM) was comparable to K d 's determined for human brain capillary receptors for peptides such as leptin, transferrin, insulin, and insulin-like growth factors (41). The binding maximum of the high-affinity sA␤ BBB sites was at least an order of magnitude higher than for the peptide hormones. The second class of lower affinity sites (K d ϭ 52.8 nM) exhibited 4.2-fold greater binding capacity than the high-affinity sites. The inhibition studies indicated that RAGE and SR are receptors involved in binding of free sA␤ at the apical side of the BBB. In contrast, the BBB binding and transport of A␤ complexed to apolipoprotein J (apoJ) is mediated via gp330/megalin (38) , and this receptor does not recognize the free form of peptide. The specific transport system mediating asymmetrical apicalto-basolateral transcytosis of free sA␤ was also found. The affinity constant of human BBB sA␤ 1-40 transporters (45 nM) compares well with the initially reported K m of 42 nM for saturable sA␤ BBB transport in vivo in rodents (20) . Transport was partially sensitive to RAGE blockade but also involved a RAGE-independent component, possibly a novel cellular "chaperone" transporter protein for sA␤.
The lack of specific sA␤ binding at the basolateral side of the HBMEC monolayer suggests that all specific high-affinity binding sites at normal human BBB may be located at the apical side, similar as for insulin (30) . The polarity of the BBB in present HBMEC model (24, 25) seems to be preserved (42) , as indicated by cellular distribution of the A amino acid transporter and enrichment of the sodium pump at the basolateral side (Stins, M., S. Jovanovic, J.B. Mackic, K.S. Kim, and B.V. Zlokovic, unpublished observations). Previous work on in vitro BBB models indicated that several peptides (e.g., vasopressin, atrial natriuretic peptide) in contrast to sA␤ are taken up by specific mechanisms only at the basolateral side followed by transendothelial transport and exocytosis at the apical side, while apical-to-basolateral transport was undetectable (16) . In the absence of significant brain-to-blood transport of sA␤, rapid clearance of sA␤ from the CSF, as reported in rodents (43) , could be important to maintaining low concentrations of sA␤ in brain extracellular fluids. It is likely that present in vitro findings could be extrapolated to humans in vivo, since the in vivo evidence in rodents and nonhuman primates confirms the net sA␤ 1-40 BBB transport from bloodto-brain (20) (21) (22) (23) 44) .
In addition to clearance, it is likely that brain metabolism serves to maintain low levels of sA␤ in cerebrovascular and brain interstitium to balance the effects of BBB transport of circulating sA␤ and local brain production of peptide, which both would tend to accumulate sA␤ in brain. In contrast to metabolism of sA␤ in brain in vivo (22, 44) , there was minimal degradation of peptide by the HBMECs. The failure in degradation mechanisms combined with an enhanced apicalto-basolateral sA␤ transport, as in senescent squirrel monkey (22) , may enhance the development of cerebral amyloid angiopathy and increase sA␤ accumulation in brain. Whether this same situation applies to BBB mechanisms in AD remains to . SR-transfected Bowes cells were incubated with sA␤ 1-40 at 37ЊC for 2 h. Cells were exposed to heparin containing buffer to elute surface bound A␤ (CI), or were exposed to heparin followed by permeabilization with NP-40 containing buffer (CII). Immunocytochemistry to visualize A␤ was performed as described in the text. be elucidated. It has been suggested that A␤ produced in brain may favor amyloid "nucleation" (45) along with other components, e.g., zinc and apoE, to accumulate soluble sA␤ from blood and CSF (1, 2, 46) . At critical levels (47) , and in the presence of other predisposing factors (e.g., apoE4 genotype, mutations in presenilin 1 and 2 genes, and mutations in amyloid-␤ protein precursor gene) (1) sA␤ may precipitate as amyloid fibril in the vascular wall or in brain parenchyma, could exert its cytotoxic effects (3) (4) (5) and contribute to neuronal loss and the development of AD pathology (1) .
Present findings support the vascular theory by demonstrating that brain endothelial distribution of A␤ receptors at the apical side of the BBB could be responsible for interaction of circulating sA␤ with the vessel wall, both for removal of this peptide from plasma and possibly for inducing endothelial cell injury (48, 49) . The list of specific receptor-and/or carriermediated BBB mechanism(s) participating in cerebrovascular accumulation, deposition, and brain transfer of blood-borne A␤ , the Dutch mutant vasculotropic peptide (A␤Q) (22) and A␤ free or complexed with apoJ and apoE4 (21, 32, 38) , and/or mediating vascular endothelial damage by A␤ (3, 4, 48, 49) includes gp330/megalin, RAGE, SR, low-and highdensity lipoprotein receptors, vascular adhesion molecules, endoplasmic reticulum-associated A␤ binding protein (35) and possibly yet unidentified receptors/transporters.
The BBB permeability to A␤-apoJ complex via gp330/ megalin receptor was among the highest ever measured for peptides/proteins at the BBB (38) . The gp330/megalin at the BBB works with the maximal transport capacity at physiological plasma concentrations of apoJ (50) , but despite its extremely high affinity for A␤-apoJ, this receptor does not transport or bind free A␤ at the BBB (38) . The present study reveals that RAGE and SR are responsible for BBB binding of free A␤. Both the RAGE and SR are well known as receptors with multiple functions including cellular endocytosis and transcytosis of macromolecules (3, 51) . Our studies support the potential of RAGE and SR type A to interact with sA␤ 1-40 mediating surface binding and, potentially, subsequent cellular processing of the ligand. In terms of endocytosis of cell-bound A␤, SR type A appears to be much more efficient than RAGE. However, RAGE may function to pass off A␤ to other binding sites mediating passage through the endothelial monolayer by mechanisms not adequately modeled in our transfected cell system. Since the transfection studies were performed in CHO and Bowes cells to examine separately the contributions of RAGE and SR, respectively, rather than endothelium, quantitative comparisons of the data are difficult to make. Clearly, the crucial test of our hypothesis concerning receptor-dependent interactions of intravascular A␤ will be in in vivo studies using specific reagents to block contribution individually of each receptor to cellular handling of A␤.
With respect to A␤ BBB transcytosis, the present study suggests the involvement of RAGE but also indicates a possible role for a RAGE-independent component that may be a novel cytosolic A␤ "chaperone" transporter protein. The molecular nature of this chaperone transporter protein remains to be elucidated, as well as its functional relationship with RAGE. It is possible that both RAGE and chaperone protein exhibit similar kinetic affinities to transport A␤ in the present HBMEC model, so that Michealis-Menten analysis revealed a single transport site. Alternatively, the affinity of one of these components may be at the lower limit of sensitivity with the present method, and molecular isolation and characterization from cytosolic and cell membrane fractions should demonstrate whether the transporter protein is different from known A␤-binding proteins and/or receptors. The distribution of cerebrovascular endothelial receptors for free and bound forms of A␤ in AD is unknown, but it is likely that they could play important roles in A␤ vascular binding and transport, and therefore influence the development of cerebrovascular amyloidosis and vascular injury.
